Caris & Co Initiates Coverage on Elan Corp. (ELN) with a Sell
More News related to ELN
- Notable Analyst Rating Changes 8/29: CBT, NZ, INCY Upgraded; WBD, ENER, WSM Downgraded
- Pre-Open Movers 8/29: Dell Falls On Earnings/Margin Miss, Magma Design (LAVA) Down on Results/Guidance
- Morgan Stanley Starts Elan (ELN) at Overweight
- FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
- Deutsche Bank Notes Tysabri PML Patients are Recovering (BIIB, ELN)
Caris & Co initiates coverage on Elan Corp. (NYSE: ELN) with a Sell. Price target $18.
Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT)
Related Categories
New CoverageStocks Mentioned
-0.21Comments
Elan
Hey! I bought this stock at $3.00 a share. And I stil think its has room to go up. So I'm still holding on to it for awhile.
Elan
some one is always trying to drive price down But it always comes back higer. these guys know nothing
Elan - Sell advisory
never heard of u guys...u must be shorting Eln....this stock could double in time...
Elan - Sell advisory
Your organization can not be taken seriously with a sell on Elan. No one can tell for sure, but Elan's Stock is like holding a lottery ticket with Tysabri as a nice backstop.
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
ELN touched 37 recently
Jan on Jul 25, 2008 11:21 PMJust curious if Caris is comfortable with their $18 target?